Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

about

Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E.CD73 expression and clinical significance in human metastatic melanoma.

P2860

Q55251496-242B3817-7763-4CD3-9DEE-D76355FEE185 Q55282181-D5902589-0B50-4279-B3AA-CE2419CD4713

P2860

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

Item

http://www.wikidata.org/entity/Q47395423

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Clinical significance of CD73 ...... of a phase III clinical trial.

@en

Clinical significance of CD73 ...... of a phase III clinical trial.

@nl

type

Item

label

Clinical significance of CD73 ...... of a phase III clinical trial.

@en

Clinical significance of CD73 ...... of a phase III clinical trial.

@nl

prefLabel

Clinical significance of CD73 ...... of a phase III clinical trial.

@en

Clinical significance of CD73 ...... of a phase III clinical trial.

@nl

P1476

Clinical significance of CD73 ...... of a phase III clinical trial

@en

P2093

B Allard

http://www.w3.org/2001/XMLSchema#string

C Sotiriou

http://www.w3.org/2001/XMLSchema#string

I Cousineau

http://www.w3.org/2001/XMLSchema#string

J P A Crown

http://www.w3.org/2001/XMLSchema#string

J Stagg

http://www.w3.org/2001/XMLSchema#string

K Willard-Gallo

http://www.w3.org/2001/XMLSchema#string

L Ameye

http://www.w3.org/2001/XMLSchema#string

M Bergeron

http://www.w3.org/2001/XMLSchema#string

M Paesmans

http://www.w3.org/2001/XMLSchema#string

M Piccart-Gebhart

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting

CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

The roles of CD73 in cancer

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.

Triple-negative breast cancer: clinical features and patterns of recurrence.

Use of archived specimens in evaluation of prognostic and predictive biomarkers

Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists

Image Analysis of the Tumor Microenvironment.

P304

1056-1062

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDX730

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sherene Loi

Angelo Di Leo

L Buisseret

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29145561

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

5913595

http://www.w3.org/2001/XMLSchema#string

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

about

P2860

P2860

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932